Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genmab ( (GMAB) ) has shared an announcement.
On January 16, 2026, Genmab reported topline Phase 3 results from its global EPCORE DLBCL-1 trial of subcutaneous bispecific antibody epcoritamab in patients with relapsed or refractory diffuse large B‑cell lymphoma who were ineligible for high‑dose chemotherapy and autologous stem cell transplant. The study, which enrolled 483 patients and compared epcoritamab monotherapy with standard chemo‑immunotherapy regimens R‑GemOx or BR, showed a statistically significant improvement in progression‑free survival and gains in complete response rate, duration of response and time to next treatment, while overall survival did not reach statistical significance and safety findings appeared consistent with the known profile. Genmab and partner AbbVie plan to discuss the data with global regulators and continue to position epcoritamab as a potential core therapy across B‑cell malignancies, supported by multiple ongoing Phase 3 programs in both frontline and relapsed DLBCL and follicular lymphoma that could further expand its clinical and commercial footprint if successful.
The most recent analyst rating on (GMAB) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s strong financial performance and positive earnings call sentiment are the primary drivers of its score. The company’s strategic initiatives and solid valuation further support its potential, despite some technical indicators suggesting caution.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is a Denmark-based biotechnology company focused on the discovery and development of antibody-based therapies for cancer, leveraging proprietary bispecific antibody technologies such as DuoBody. Its marketed portfolio includes the T-cell engaging bispecific antibody epcoritamab, approved under the brand names EPKINLY and TEPKINLY for certain lymphoma indications in more than 65 countries, and it co-develops and commercializes this therapy globally in partnership with AbbVie, targeting a broad range of B‑cell and other hematologic malignancies.
Average Trading Volume: 1,824,231
Technical Sentiment Signal: Buy
Current Market Cap: $21.54B
See more data about GMAB stock on TipRanks’ Stock Analysis page.